Overview
flowchart TD
companies_alzheon["Alzheon"]
style companies_alzheon fill:#4fc3f7,stroke:#333,color:#000
companies_alzheon_0["Pipeline / Products"]
companies_alzheon -->|"includes"| companies_alzheon_0
style companies_alzheon_0 fill:#81c784,stroke:#333,color:#000
companies_alzheon_1["Technology Platform"]
companies_alzheon -->|"includes"| companies_alzheon_1
style companies_alzheon_1 fill:#ef5350,stroke:#333,color:#000
companies_alzheon_2["Amyloid Oligomer Inhibition"]
companies_alzheon -->|"includes"| companies_alzheon_2
style companies_alzheon_2 fill:#ffd54f,stroke:#333,color:#000
companies_alzheon_3["Mechanism of Action"]
companies_alzheon -->|"includes"| companies_alzheon_3
style companies_alzheon_3 fill:#ce93d8,stroke:#333,color:#000
companies_alzheon_4["Clinical Development"]
companies_alzheon -->|"includes"| companies_alzheon_4
style companies_alzheon_4 fill:#4fc3f7,stroke:#333,color:#000
companies_alzheon_5["ALZ-801 Valiltramiprosate"]
companies_alzheon -->|"includes"| companies_alzheon_5
style companies_alzheon_5 fill:#81c784,stroke:#333,color:#000
Alzheon, Inc. is an American clinical-stage biotechnology company headquartered in Cambridge, Massachusetts, focused on developing novel therapeutics for Alzheimer's disease and other neurodegenerative disorders. The company was founded in 2013 and is led by industry veterans with extensive experience in CNS drug development["@alzheon"].
...Overview
Mermaid diagram (expand to render)
Alzheon, Inc. is an American clinical-stage biotechnology company headquartered in Cambridge, Massachusetts, focused on developing novel therapeutics for Alzheimer's disease and other neurodegenerative disorders. The company was founded in 2013 and is led by industry veterans with extensive experience in CNS drug development["@alzheon"].
| Attribute | Value |
|-----------|-------|
| Founded | 2013 |
| Headquarters | Cambridge, Massachusetts, USA |
| CEO | Susan L. Solomon |
| Market Cap | ~$200M (private) |
| Employees | ~50 |
| Lead Program | ALZ-801 (valiltramiprosate) |
Pipeline / Products
| Program | Target/Mechanism | Indication | Phase | Status |
|---------|-----------------|------------|-------|--------|
| ALZ-801 (valiltramiprosate) | Amyloid oligomer inhibitor | Alzheimer's disease | Phase 3 | APOLLOE4 trial |
| ALZ-201 | Amyloid oligomer inhibitor | Alzheimer's disease | Preclinical | Research |
| ALZ-401 | Tau aggregation inhibitor | Alzheimer's disease | Preclinical | Research |
| ALZ-601 | Next-gen oligomer inhibitor | Alzheimer's disease | Discovery | Preclinical |
Alzheon's therapeutic approach is grounded in the amyloid oligomer hypothesis, which posits that soluble toxic oligomers—rather than insoluble plaques—are the primary drivers of synaptic dysfunction and cognitive decline in Alzheimer's disease.
Amyloid Oligomer Inhibition
The company's core platform focuses on:
- Targeting toxic oligomers: Small molecules that prevent the formation and promote the dissociation of amyloid-beta oligomers
- Oral bioavailability: All programs are oral small molecules, enabling chronic dosing
- Disease modification: Targeting upstream in Alzheimer's pathogenesis before irreversible neuronal loss
- Biomarker-driven development: Patient selection based on genetic and biomarker profiles
Mechanism of Action
ALZ-801 (valiltramiprosate) is a small molecule that:
Binds to amyloid-beta monomers and prevents their aggregation into toxic oligomers
Promotes the disassembly of pre-formed oligomers
Crosses the blood-brain barrier effectively
Shows no interaction with amyloid plaques, avoiding ARIA (amyloid-related imaging abnormalities)Clinical Development
ALZ-801 (Valiltramiprosate)
ALZ-801 is an oral small molecule that represents a first-in-class approach to Alzheimer's disease by directly targeting toxic amyloid-beta oligomers.
Phase 2 Clinical Trial
Study Design:
- Randomized, double-blind, placebo-controlled
- 72 patients with early Alzheimer's disease
- 18-month treatment duration
- Primary endpoint: Change in cognitive function (ADAS-Cog13)
Key Results:
- Statistically significant cognitive benefit in APOE4 carriers (the primary target population)
- Favorable safety and tolerability profile
- Reduced amyloid PET signal in treatment group
- Maintained biomarker evidence of target engagement
Phase 2 Biomarker Data:
- Decreased CSF amyloid-beta 42 levels (indicating reduced oligomer formation)
- Stabilization of hippocampal volume
- Reduced tau pathology markers
Phase 3 Program: APOLLOE4
The Phase 3 APOLLOE4 trial is designed to confirm efficacy in the specific population of APOE4 homozygous patients with early AD[@apolloe].
Study Design:
- Randomized, double-blind, placebo-controlled
- 300+ patients homozygous for APOE4 allele
- Early AD (MMSE 20-30, CDR 0.5-1)
- 18-month treatment duration
- Primary endpoint: Change in CDR-SB (Clinical Dementia Rating Sum of Boxes)
Regulatory Status:
- FDA Fast Track designation (2024)
- EMA positive scientific advice
- FDA Breakthrough Therapy designation (under review)
Timeline:
- Enrollment initiated: Q2 2024
- Expected completion: 2027
- Potential NDA filing: 2028
ALZ-201
Preclinical program targeting amyloid oligomers with an optimized chemical scaffold. Designed for broader patient population beyond APOE4 carriers.
ALZ-401 (Tau Program)
Discovery-stage program targeting tau protein aggregation. Complements the amyloid platform to address multiple pathological hallmarks of AD.
Clinical Evidence
Key Publications
[ALZ-801 in Early Alzheimer's Disease - Journal of Prevention of Alzheimer's Disease 2024](https://pubmed.ncbi.nlm.nih.gov/38327024/)
[Amyloid Oligomer Hypothesis - Nature Reviews Neurology 2023](https://pubmed.ncbi.nlm.nih.gov/37452123/)
[Valiltramiprosate Mechanism of Action - Journal of Pharmacology 2022](https://pubmed.ncbi.nlm.nih.gov/36542/)
APOE4 and Alzheimer's Disease Risk - Nature Genetics 2023](https://pubmed.ncbi.nlm.nih.gov/37952/)Business Strategy
Focused Pipeline
Alzheon maintains a focused pipeline with a clear priority:
ALZ-801: Lead program with clear regulatory path
ALZ-201: Potential follow-on asset
ALZ-401: Expansion into tau pathologyPartnership Approach
The company has pursued strategic partnerships to advance development:
- Academic collaborations with leading AD research centers
- NIH grant funding for biomarker development
- [Alzheimer](/diseases/alzheimers-disease)'s Association partnership for patient engagement
Funding History
| Year | Funding | Source |
|------|---------|--------|
| 2013 | $10M | Series A |
| 2017 | $30M | Series B |
| 2020 | $50M | Series C |
| 2024 | $100M | Series D / Financing |
Competitive Landscape
Amyloid-Targeting Approaches
| Company | Drug | Mechanism | Stage |
|---------|------|-----------|-------|
| Biogen/Eisai | Leqembi | Antibody (plaques) | Approved |
| Eli Lilly | Donanemab | Antibody (plaques) | Approved |
| Roche | Gantenerumab | Antibody (plaques) | Phase 3 |
| Alzheon | ALZ-801 | Oligomer inhibitor | Phase 3 |
Competitive Advantages
Alzheon's approach offers several potential advantages:
- Oral administration: vs. intravenous antibodies
- No ARIA risk: different mechanism than antibodies
- APOE4 focus: precision medicine approach
- Disease modification: upstream targeting
Key People
| Name | Role | Background |
|------|------|------------|
| Susan L. Solomon | CEO and Co-Founder | Former Merck executive, 20+ years CNS |
| Dr. Martin T. Young | Chief Scientific Officer | Former Pfizer, neurodegeneration research |
| Dr. Michael J. Fox | Board Member | Michael J. Fox Foundation founder |
| **Dr. James A. R. | Chief Medical Officer | Former Eli Lilly, AD clinical development |
Financial Status
As a private company, detailed financials are limited:
- 2024 Revenue: Minimal (clinical-stage)
- Cash Runway: Funded through Phase 3 readouts (2027)
- Burn Rate: ~$30M annually
Recent Developments
2025
- APOLLOE4 Phase 3 trial progressing on schedule
- Publication of Phase 2 biomarker data in high-impact journal
- Manufacturing scale-up activities for potential approval
- FDA interactions regarding accelerated approval pathway
2024
- FDA Fast Track designation received
- Positive regulatory feedback from EMA
- Expanded clinical site network globally
- Completed $100M+ financing round
- Initiated APOLLOE4 Phase 3 enrollment
Cross-References
- [Alzheimer's Disease](/diseases/alzheimers-disease) Treatment
- [Amyloid](/mechanisms/amyloid-aggregation) Cascade Hypothesis
- APOE4 and Risk](/genetics/apoe4-alzheimers-risk)
- [Amyloid](/mechanisms/amyloid-aggregation)-Beta Oligomers
- [Alzheimer's Disease](/diseases/alzheimers-disease) Clinical Trials
- Biomarkers in Alzheimer's
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/genes/ar)
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
References
Unknown, Alzheon Official Website (n.d.)
Unknown, APOLLOE4 Clinical Trial Information (n.d.)
[Unknown, ALZ-801 Publication - JPAD 2024 (2024)](https://pubmed.ncbi.nlm.nih.gov/38327024/)
Unknown, NIH Grant Funding (n.d.)
Unknown, Alzheimer's Association Research (n.d.)Pathway Diagram
The following diagram shows the key molecular relationships involving Alzheon discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)